Pantex40 mg/vial

Established / FDA-Approved Uses

• Gastroesophageal reflux disease (GERD) and short-term treatment of erosive esophagitis associated with GERD, and maintenance of healing of erosive esophagitis.
• Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Guideline-Supported / Widely Accepted Uses

• Peptic ulcer disease (gastric and duodenal ulcer), including healing of benign gastric ulcers.
• Prevention and healing of NSAID-associated gastric and duodenal ulcers in patients who require continued NSAID therapy.

Adjunct / Combination-Therapy Use

• As part of multi-drug regimens for eradication of Helicobacter pylori (used together with appropriate antibiotics such as amoxicillin and clarithromycin, not as monotherapy).

Pantex is a proton pump inhibitor (PPI) used to reduce excess stomach acid production in the conditions above.

Each tablet/vial contains Pantoprazole (as pantoprazole sodium sesquihydrate) as the active ingredient. Available strengths marketed include 20 mg and 40 mg delayed-release (enteric-coated) tablets, and 40 mg powder for injection (IV) for use when oral therapy is not possible. Inactive ingredients vary by manufacturer and formulation.

Pantex is a substituted benzimidazole that belongs to the proton pump inhibitor (PPI) class of medicines. It works by irreversibly blocking the hydrogen-potassium ATPase ("proton pump") in the gastric parietal cells, which is the final step in stomach acid secretion. By reducing acid production, Pantex relieves symptoms and promotes healing in acid-related disorders such as GERD, erosive esophagitis, peptic ulcer disease and hypersecretory conditions like Zollinger-Ellison syndrome. It is formulated as a delayed-release (enteric-coated) oral tablet, and also as an intravenous injection for patients unable to take oral medication.

Proton Pump Inhibitor (PPI) - Anti-ulcerant / Gastric acid-reducing agent.

Mechanism of Action

Pantoprazole is a prodrug that is activated in the acidic environment of the gastric parietal cell canaliculus. Once activated, it covalently and irreversibly binds to cysteine residues on the H+/K+-ATPase (proton pump) enzyme, blocking the final step of gastric acid secretion regardless of the stimulus (histamine, acetylcholine, or gastrin). Because the binding is irreversible, acid suppression persists until new proton pump molecules are synthesized (typically 24-48 hours), giving Pantoprazole a duration of action longer than its plasma half-life would suggest.

Pharmacokinetics

• Absorption: Well absorbed after oral administration of the enteric-coated formulation; peak plasma concentration reached in about 2-2.5 hours.
• Metabolism: Extensively metabolized in the liver, mainly via CYP2C19, with a minor contribution from CYP3A4.
• Elimination half-life: Approximately 1 hour, although the duration of acid suppression is much longer due to irreversible enzyme binding.
• Excretion: Predominantly renal (about 80%), with the remainder eliminated in feces via biliary excretion.

Pantex delayed-release tablets should be swallowed whole with water, without crushing, splitting or chewing, generally in the morning before a meal. It may be taken with or without food. The injectable form is given intravenously by a healthcare provider for patients who cannot take oral medication.

Clinically Significant Drug Interactions

• Rilpivirine-containing HIV medicines: Pantex reduces gastric acidity, significantly decreasing rilpivirine absorption and effectiveness; concurrent use is contraindicated.
• Atazanavir, nelfinavir: Reduced absorption and plasma levels due to decreased gastric acidity, potentially leading to loss of antiretroviral efficacy; combination generally not recommended.
• Warfarin: May increase INR and prothrombin time, raising bleeding risk; monitor INR more closely when starting or stopping Pantex.
• Methotrexate (high-dose): PPIs may elevate and prolong serum methotrexate levels, increasing toxicity risk; temporary withdrawal of Pantex may be considered during high-dose methotrexate therapy.
• Mycophenolate mofetil: Reduced exposure to the active metabolite in transplant patients, which could affect graft outcomes.
• Drugs requiring gastric acid for absorption (e.g. ketoconazole, itraconazole, certain iron salts): Absorption may be reduced by the acid-suppressing effect of Pantex.
• CYP2C19 substrates/inhibitors: Since Pantex is metabolized via CYP2C19, drugs that strongly affect this enzyme may alter its plasma levels, though clinically significant effects are uncommon at standard doses.

Common

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Flatulence
• Dizziness

Less Common / Rare but Notable

• Rash, pruritus
• Insomnia
• Hyperglycemia
• Elevated liver enzymes
• Hypomagnesemia, vitamin B12 deficiency, bone fracture risk, and Clostridioides difficile-associated diarrhea with long-term use (see Precautions and Warnings for details)

Pregnancy: Available human data have not established a clear association between Pantex use and major birth defects or miscarriage; however, animal studies have shown bone changes in offspring at high doses. Pantex should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: Pantex passes into breast milk in small amounts. Available data have not shown adverse effects in breastfed infants, but caution is advised; a physician should be consulted to weigh the benefits of treatment against any potential risk to the infant.

Bone Fracture Risk

Long-term use (especially at high doses for one year or more) of Pantex and other PPIs is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, and spine. Use the lowest effective dose for the shortest duration appropriate to the condition.

Hypomagnesemia

Prolonged treatment (three months or longer) with Pantex may cause low serum magnesium, which can present as tetany, arrhythmias, or seizures. Magnesium levels may be checked before and periodically during prolonged therapy, especially with concurrent diuretics or other drugs that lower magnesium.

Vitamin B12 Deficiency

Daily use of Pantex for longer than 3 years may reduce absorption of vitamin B12 due to hypo- or achlorhydria, potentially resulting in deficiency.

Clostridioides difficile-Associated Diarrhea

Pantex therapy, like other PPIs, may increase the risk of C. difficile-associated diarrhea, particularly in hospitalized patients. Consider this diagnosis in patients who develop persistent diarrhea that does not improve.

Masking of Gastric Malignancy

Symptomatic relief with Pantex does not exclude the presence of gastric malignancy. Consider further evaluation in patients with alarm symptoms (e.g. weight loss, recurrent vomiting, dysphagia, hematemesis) or those with an inadequate or non-durable response to therapy.

Rebound Acid Hypersecretion

Discontinuing Pantex after prolonged use may lead to a temporary increase in acid-related symptoms (rebound acid hypersecretion). Consider tapering under medical advice rather than stopping abruptly after long-term therapy.

Cutaneous and Systemic Lupus Erythematosus

Rare cases of new-onset or exacerbated lupus erythematosus have been reported with PPI use, including Pantex; discontinue and refer to a specialist if lesions develop.

Pantex is not an antibiotic and does not carry antimicrobial stewardship requirements; however, it should still be taken exactly as prescribed by a physician, without altering the dose or duration on one's own.

There is limited clinical experience with deliberate Pantex overdose. Doses well above the usual therapeutic range have generally been tolerated without severe symptoms. There is no specific antidote for Pantex overdose, and it is not effectively removed by hemodialysis. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, based on clinical presentation.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

The safety and effectiveness of Pantex for short-term treatment of erosive esophagitis due to GERD have been established in children aged 5 years and older; dosing is weight-based (see Pediatric Uses). Safety and efficacy in children under 1 year of age have not been established, and studies in infants did not demonstrate efficacy.

Elderly Use

No overall dosage adjustment is required for elderly patients, although they may be at higher baseline risk for some long-term PPI-associated effects (e.g. bone fracture); use the lowest effective dose for the shortest necessary duration.

Renal Impairment

No dosage adjustment of Pantex is generally required in renal impairment, including patients on hemodialysis.

Hepatic Impairment

In patients with severe hepatic impairment, consider a reduced dose and monitor liver enzymes periodically during treatment with Pantex.

Duration depends on indication: typically 4-8 weeks for GERD/erosive esophagitis or ulcer healing (occasionally extended for another 8 weeks if not fully healed); ongoing maintenance dosing for chronic erosive esophagitis or hypersecretory conditions; and 7-14 days when used as part of combination therapy for H. pylori eradication. Pantex should not be used for longer than medically advised without reassessment, given the risks associated with long-term PPI therapy.

The 40 mg powder for injection is reconstituted with 10 mL of 0.9% Sodium Chloride Injection to a concentration of approximately 4 mg/mL, and may be further diluted for infusion per the product's prescribing information; reconstitution should only be performed by a trained healthcare professional.

Proton pump inhibitor (PPI); substituted benzimidazole; gastric acid-reducing / anti-secretory agent.

Pantoprazole selectively and irreversibly inhibits the H+/K+-ATPase (proton pump) enzyme system located on the secretory surface of gastric parietal cells. This enzyme is responsible for the final step of gastric acid production. By blocking it, Pantoprazole suppresses both basal and stimulated gastric acid secretion, irrespective of the stimulating agent (gastrin, histamine, or acetylcholine), producing a profound and long-lasting reduction in stomach acid.

B

Pantex is approved for short-term (up to 8 weeks) treatment of erosive esophagitis associated with GERD in children aged 5 to 16 years, using weight-based dosing: 20 mg once daily for children weighing 15 kg to less than 40 kg, and 40 mg once daily for children weighing 40 kg or more. Safety and efficacy for other indications, and use in children under 5 years of age (including infants), have not been established; studies conducted in infants younger than 1 year did not show efficacy for GERD symptoms. Use in children should be guided and supervised by a pediatrician.